TRIM24 and cancer: Supporting this hypothesis, an increased rate of somatic mutations and loss of heterozygosity was observed in the genes encoding TIF1 in tumour DNA from anti-TIF1 positive cancer-associated myositis patients compared to anti-TIF1-negative myositis patients (35).